Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NHC-APL2018/CCLG-APL2018 protocol for childhood acute promyelocytic leukemia
ChiCTR1800019726Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Dec 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of tretinoin, arsenic trioxide and Compound Huangdai Tablet in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoints: Hematologic complete remission, Molecular complete remission and 2 more. Started Dec 2018; status: recruiting.
02
Drugs
tretinoinarsenic trioxideCompound Huangdai Tablet
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR1800019726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019726.